


## DOTA-PEG5-C6-DBCO

Cat. No.:	HY-140314		
Molecular Formula:	C <sub>49</sub> H <sub>71</sub> N <sub>7</sub> O <sub>14</sub>		
Molecular Weight:	982.13		
Target:	PROTAC Linkers		
Pathway:	PROTAC		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 125 mg/mL (127.27 mM; ultrasonic and warming and heat to 60°C)  
 DMSO : 125 mg/mL (127.27 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		Concentration	1 mg	5 mg	10 mg
	1 mM		1.0182 mL	5.0910 mL	10.1820 mL
	5 mM		0.2036 mL	1.0182 mL	2.0364 mL
	10 mM		0.1018 mL	0.5091 mL	1.0182 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

DOTA-PEG5-C6-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs<sup>[1]</sup>. DOTA-PEG5-C6-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

#### IC<sub>50</sub> & Target

PEGs

#### In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA